Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 11, 2004

View Archived Issues

Antibody targeting melanoma glycoprotein-proteoglycan complex shows anticancer efficacy in vivo

Preliminary phase II data on the antitumor efficacy of TG-4010 in NSCLC

Glycotope-specific antibody shows cytotoxic activity against gastrointestinal tumor in vivo

Anti-VEGFR antibody reduces lymphangiogenesis in vivo

A selective LXR agonist shows promise as an antiatherosclerotic agent

Novel NMDA GlyB-site antagonists discovered at Gruenenthal

Bayer claims new proteasome inhibitors for asthma and cancer

Novel tachykinin NK2/NK3 ligands discovered at Merck

New 5-HT1A ligands/5-HT reuptake inhibitors covered by Merck KGaA patent

Novartis scientists prepare and test new protein kinase C inhibitors

New CDK inhibitors in early development at Pfizer

New inhibitors of ERK2, GSK-3, PKA and CDK2 presented by Vertex

U.K. manufacturing for Fluvirin fails to comply with GMP regulations

rHuEPO active in wound healing

VEGF-toxin fusion protein inhibits tumor growth in vivo

Anti-PDGF receptor alpha antibody shows promising results in rodent glioblastoma model

Cytotoxic agent by Tapestry shows higher potency than paclitaxel in vitro

MDX-060 receives orphan drug status for Hodgkin's disease

MRL-123 decreases bone resorption and increases BMD in osteoporotic women

MC-45308 demonstrates simultaneous antiplatelet and anticoagulant effects

A product derived from bovine colostrum reduces the effects of HIV-associated diarrhea

Photrex chosen as new brand name for SnET2

Sustained reduction of testosterone levels achieved with Eligard 45 mg in prostate cancer patients

Good safety profile reported for HGS-ETR2 in advanced cancer patients

Santhera grants Genzyme license for discovery of therapies for muscular diseases

Six-month priority review for Pegasys sBLA

Expansion of Biolex and Centocor collaboration

Target enrollment reached in phase II study of methylnaltrexone for POI

New phase I study of aminocandin for systemic invasive fungal infections

MG-98 enters phase II study in metastatic renal cell cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...